Replimune Group Inc REPL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if REPL is a good fit for your portfolio.
News
-
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
-
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
-
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
-
Replimune to Present at Three Upcoming Investor Conferences
-
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
-
Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals
Trading Information
- Previous Close Price
- $6.56
- Day Range
- $6.61–7.08
- 52-Week Range
- $5.86–24.81
- Bid/Ask
- $6.93 / $6.95
- Market Cap
- $426.65 Mil
- Volume/Avg
- 631,256 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.06%
Company Profile
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 284
- Website
- https://www.replimune.com
Comparables
Valuation
|
Metric
|
REPL
|
CLDX
|
MRSN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.01 | 5.54 | 11.32 |
Price/Sales | — | 299.58 | 10.90 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
REPL
|
CLDX
|
MRSN
|
|---|---|---|---|
Quick Ratio | 12.18 | 13.69 | 3.29 |
Current Ratio | 12.40 | 13.87 | 3.36 |
Interest Coverage | −32.32 | — | −44.11 |
Quick Ratio
REPL
CLDX
MRSN
Profitability
|
Metric
|
REPL
|
CLDX
|
MRSN
|
|---|---|---|---|
Return on Assets (Normalized) | −29.81% | −30.49% | −49.57% |
Return on Equity (Normalized) | −35.34% | −33.19% | −211.52% |
Return on Invested Capital (Normalized) | −30.55% | −32.85% | −146.81% |
Return on Assets
REPL
CLDX
MRSN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mqkzcbzcy | Lsv | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rgwggbh | Qlrnjns | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lnmpsykh | Bjtfksq | $103.7 Bil | |
MRNA
| Moderna Inc | Kfnwzgj | Scdss | $47.9 Bil | |
ARGX
| argenx SE ADR | Fxrlwxdnm | Hbg | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Hhtmvqk | Dxk | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mzzwcjzf | Gbsgh | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nzflwrz | Cdylwhq | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xyzhfnyfwd | Fqwvqr | $12.8 Bil | |
INCY
| Incyte Corp | Thdgdwzb | Lsznx | $12.1 Bil |